Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ABEO | US
0.06
1.07%
Healthcare
Biotechnology
30/06/2024
02/06/2026
5.69
5.60
5.72
5.54
Abeona Therapeutics Inc. a clinical-stage biopharmaceutical company develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101 an autologous engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York New York.
View LessPositive Momentum
Low Debt to Asset (< 0.2)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
45.5%1 month
53.2%3 months
47.4%6 months
45.9%-
-
3.99
0.32
0.17
-0.58
53.29
-
-54.75M
246.46M
246.46M
-
-
-
-100.00
-127.38
11.83
6.35
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.85
Range1M
0.99
Range3M
1.84
Rel. volume
0.64
Price X volume
4.29M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Candel Therapeutics Inc. Common Stock | CADL | Biotechnology | 8.42 | 270.15M | -1.06% | n/a | -186.13% |
| Rocket Pharmaceuticals Inc | RCKT | Biotechnology | 2.89 | 262.92M | -4.30% | n/a | 6.71% |
| Northwest Biotherapeutics Inc | NWBO | Biotechnology | 0.205 | 256.92M | -7.11% | n/a | 0.00% |
| Moolec Science SA Ordinary Shares | MLEC | Biotechnology | 6.83 | 255.86M | -0.29% | n/a | 209.19% |
| Enanta Pharmaceuticals Inc | ENTA | Biotechnology | 12.03 | 254.90M | -5.05% | n/a | 151.88% |
| MacroGenics Inc | MGNX | Biotechnology | 4.05 | 254.02M | -2.17% | n/a | 58.90% |
| Solid Biosciences Inc | SLDB | Drug Manufacturers-Specialty & Generic | 6.58 | 253.96M | -8.48% | n/a | 13.09% |
| Verrica Pharmaceuticals Inc | VRCA | Biotechnology | 5.79 | 247.05M | -1.86% | n/a | -348.20% |
| Entrada Therapeutics Inc. Common Stock | TRDA | Biotechnology | 6.64 | 247.01M | -3.91% | 5.77 | 14.99% |
| DiaMedica Therapeutics Inc | DMAC | Biotechnology | 5.77 | 246.65M | -1.20% | n/a | 0.73% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Urban One Inc | UONEK | Broadcasting - Radio | 4.7 | 249.14M | -10.36% | n/a | 268.43% |
| CPI Card Group Inc | PMTS | Building Products & Equipment | 16.74 | 186.78M | -0.42% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 11.36 | 182.41M | 2.53% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 40.57 | 116.51M | -0.44% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.01 | 97.90M | 0.84% | 9.09 | 39.79% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 7.09 | 67.49M | 2.75% | n/a | 19.98% |
| ILAG | ILAG | Building Products & Equipment | 3.6016 | 65.04M | -4.21% | n/a | 5.48% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 9.37 | 58.67M | -0.64% | 14.48 | 7.10% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 19.59 | 29.83M | 25.34% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.11 | 16.22M | -2.63% | 0.03 | 16.03% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.58 | - | Cheaper |
| Ent. to Revenue | 53.29 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.99 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 47.35 | - | Lower Risk |
| Debt to Equity | 0.32 | -1.23 | Expensive |
| Debt to Assets | 0.17 | 0.25 | Cheaper |
| Market Cap | 246.46M | - | Emerging |